According to AlphaMoat, in 2026-08 Manas AI (manasai.co) received 12,728 monthly visits (-26.3% MoM) — ranked #9,048 of 17,407 AI websites with traffic data, and #1,321 of 3,173 in Industry Services; its largest market is India (48.7% of visits).
What is Manas AI
Manas AI is an end-to-end, AI-native biopharmaceutical company headquartered in New York, USA, founded in 2025 by Siddhartha Mukherjee, Reid Hoffman, and Ujjwal Singh. It builds and uses in-house AI foundation models based on neuro-symbolic methods, physical-chemistry, and biological domain rules, focusing on aggressive cancers such as breast, prostate, and lymphoma to accelerate drug discovery and development.
- 01Its frontier neuro-symbolic AI models encode deep scientific domain rules from chemistry, physics, and biology
- 02an end-to-end pipeline covers every step from target identification to clinical trials
- 03a multi-modal platform uniformly accelerates small-molecule, antibody, and siRNA therapy R&D
- 04human-in-the-loop ensures the platform only advances the most viable and safe therapeutic candidates
- 05and its physics-plus-AI discovery platform reduces cycle times and overall costs
As a biopharmaceutical company, it creates value by advancing its own drug pipeline and conducting research collaborations with partners; the website does not publish standardized commercial product pricing, and the page lists no explicit currency price figures.
12-Month Traffic Trend
Visits by Country · Top 5
Popular in Industry Services
Data month: 2026-08 · Visit figures are third-party traffic estimates aggregated monthly — best for scale and trends. Multiple domains of the same product are merged. See methodology.